Highly diverse phenotypes of mucopolysaccharidosis type IIIB sibling patients: effects of an additional mutation in the AUTS2 gene
- PMID: 35525889
- DOI: 10.1007/s13353-022-00702-2
Highly diverse phenotypes of mucopolysaccharidosis type IIIB sibling patients: effects of an additional mutation in the AUTS2 gene
Abstract
Mucopolysaccharidosis type IIIB (MPS IIIB or Sanfilippo syndrome type B) is an inherited metabolic disease caused by mutations in the NAGLU gene, encoding α-N-acetylglucosaminidase. Accumulation of undegraded heparan sulfate (one of glycosaminoglycans) arises from deficiency in this enzyme and leads to severe symptoms, especially related to dysfunctions of the central nervous system. Here, we describe a case of two siblings with highly diverse phenotypes, despite carrying the same mutations (c.1189 T > G/c.1211G > A (p.Phe397Val/p.Trp404Ter)) and similar residual activities of α-N-acetylglucosaminidase; the younger patient reveals more severe phenotype; thus, these differences cannot be explained by the age and progression of the disease. Surprisingly, the whole exome sequencing analysis indicated the presence of an additional mutation in one allele of the AUTS2 gene (c.157G > A (p.Ala53Thr)) in the younger patient but not in the older one. Since mutations in this gene are usually dominant and cause delayed development and intellectual disability, it is likely that the observed differences between the MPS IIIB siblings are due to the potentially pathogenic AUTS2 variant, present in one of them. This case confirms also that simultaneous occurrence of two ultra-rare diseases in one patient is actual, despite a low probability of such a combination. Moreover, it is worth noting that apart from the genotype-phenotype correlation and the importance of the residual activity of the deficient enzyme, efficiency of glycosaminoglycan synthesis and global secondary changes in expression of hundreds of genes may considerably modulate the course and severity of MPS, especially Sanfilippo disease.
Keywords: Diverse phenotype; Mucopolysaccharidosis; Sanfilippo syndrome type B; Siblings.
© 2022. The Author(s), under exclusive licence to Institute of Plant Genetics Polish Academy of Sciences.
References
-
- Benetó N, Vilageliu L, Grinberg D, Canals I (2020) Sanfilippo syndrome: molecular basis, disease models and therapeutic approaches. Int J Mol Sci 21:7819. https://doi.org/10.3390/ijms21217819 - DOI - PMC
-
- Biel A, Castanza AS, Rutherford R, Fair SR, Chifamba L, Wester JC, Hester ME, Hevner RF (2022) AUTS2 syndrome: molecular mechanisms and model systems. Front Mol Neurosci 15:858582. https://doi.org/10.3389/fnmol.2022.858582 - DOI - PubMed - PMC
-
- Cyske Z, Gaffke L, Pierzynowska K, Węgrzyn G (2022) Complex changes in the efficiency of the expression of many genes in monogenic diseases, mucopolysaccharidoses, may arise from significant disturbances in the levels of factors involved in the gene expression regulation processes. Genes 13:593. https://doi.org/10.3390/genes13040593 - DOI - PubMed - PMC
-
- Di Natale P, Murino P, Pontarelli G, Salvatore D, Andria G (1982) Sanfilippo B syndrome (MPS III B): altered residual alpha-N-acetylglucosaminidase activity in an unusual sibship. Clin Chim Acta 122:135–143. https://doi.org/10.1016/0009-8981(82)90273-x - DOI - PubMed
-
- Gaffke L, Pierzynowska K, Piotrowska E, Węgrzyn G (2018) How close are we to therapies for Sanfilippo disease? Metab Brain Dis 33:1–10. https://doi.org/10.1007/s11011-017-0111-4 - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous
